{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:57:45Z","timestamp":1768741065100,"version":"3.49.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T00:00:00Z","timestamp":1342051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00787-012-0305-6","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T18:33:06Z","timestamp":1342031586000},"page":"599-610","source":"Crossref","is-referenced-by-count":32,"title":["Fluoxetine pharmacogenetics in child and adult populations"],"prefix":"10.1007","volume":"21","author":[{"given":"Ana","family":"Blazquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergi","family":"Mas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Teresa","family":"Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e0lia","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,12]]},"reference":[{"issue":"1","key":"305_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","volume":"85","author":"C Hiemke","year":"2000","unstructured":"Hiemke C, H\u00e4rtter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85(1):11\u201328","journal-title":"Pharmacol Ther"},{"issue":"11","key":"305_CR2","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2217\/14622416.9.11.1725","volume":"9","author":"S Kronenberg","year":"2008","unstructured":"Kronenberg S, Frisch A, Rotberg B, Carmel M, Apter A, Weizman A (2008) Pharmacogenetics of selective serotonin reuptake inhibitors in paediatric depression and anxiety. Pharmacogenomics 9(11):1725\u20131736","journal-title":"Pharmacogenomics"},{"key":"305_CR3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/mp.2008.116","volume":"15","author":"M Kato","year":"2010","unstructured":"Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473\u2013500","journal-title":"Mol Psychiatry"},{"issue":"2","key":"305_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1503\/jpn.100059","volume":"36","author":"S Porcelli","year":"2011","unstructured":"Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A (2011) Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 36(2):87\u2013113","journal-title":"J Psychiatry Neurosci"},{"key":"305_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0009-8981(01)00423-5","volume":"308","author":"W Steimer","year":"2001","unstructured":"Steimer W, M\u00fcller B, Leucht S, Kissling W (2001) Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308:33\u201341","journal-title":"Clin Chim Acta"},{"issue":"4","key":"305_CR6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1023\/A:1006934807375","volume":"19","author":"CL DeVane","year":"1999","unstructured":"DeVane CL (1999) Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 19(4):443\u2013466","journal-title":"Cell Mol Neurobiol"},{"key":"305_CR7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3565(24)29631-2","volume":"297","author":"BJ Ring","year":"2001","unstructured":"Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, Vandenbranden M, Wrighton SA (2001) Identification of the human cytochromes P450 responsibles for in vitro formation of R- and S-Norfluoxetine. J Pharmacol Exp Ther 297:1044\u20131050","journal-title":"J Pharmacol Exp Ther"},{"key":"305_CR8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00007691-200312000-00014","volume":"25","author":"C Charlier","year":"2003","unstructured":"Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteaux G (2003) Polymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 25:738\u2013742","journal-title":"Ther Drug Monit"},{"issue":"7","key":"305_CR9","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30(7):1206\u20131227","journal-title":"Clin Ther"},{"key":"305_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.phrs.2004.01.004","volume":"50","author":"MG Scordo","year":"2004","unstructured":"Scordo MG, Caputi AP, D\u2019Arrigo C, Fava G, Spina E (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195\u2013200","journal-title":"Pharmacol Res"},{"key":"305_CR11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1742-7843.2005.pto_194.x","volume":"97","author":"MG Scordo","year":"2005","unstructured":"Scordo MG, Spina E, Dahl M-L, Gatti G, Perucca E (2005) Influence of CYP2C9, 2C19 and D6 Genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 97:296\u2013301","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"305_CR12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00228-003-0707-y","volume":"59","author":"A Llerena","year":"2004","unstructured":"Llerena A, Dorado P, Berecz R, Gonz\u00e1lez AP, Pe\u00f1as-Lled\u00f3 EM (2004) Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 59:869\u2013873","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"305_CR13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/00004714-200212000-00006","volume":"22","author":"TE Wilens","year":"2002","unstructured":"Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N et al (2002) Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 22(6):568\u2013575","journal-title":"J Clin Psychopharmacol"},{"key":"305_CR14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.mp.4001546","volume":"9","author":"TC Eley","year":"2004","unstructured":"Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P et al (2004) Gene-environment interaction analisis of serotonin system markers with adolescent depression. Mol Psychiatry 9:908\u2013915","journal-title":"Mol Psychiatry"},{"issue":"12","key":"305_CR15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48(12):761\u2013804","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"305_CR16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48(11):689\u2013723","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"305_CR17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1586\/ern.10.186","volume":"11","author":"R Keers","year":"2011","unstructured":"Keers R, Aitchison KJ (2011) Pharmacogenetics of antidepressant response. Expert Rev Neurother 11(1):101\u2013125","journal-title":"Expert Rev Neurother"},{"key":"305_CR18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00228-008-0509-3","volume":"64","author":"JW Hinrichs","year":"2008","unstructured":"Hinrichs JW, Loovers HM, Scholten B, van der Weide J (2008) Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur J Clin Pharmacol 64:979\u2013986","journal-title":"Eur J Clin Pharmacol"},{"key":"305_CR19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","volume":"9","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442\u2013473","journal-title":"Mol Psychiatry"},{"issue":"9","key":"305_CR20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1517\/17425255.2011.597740","volume":"7","author":"S Porcelli","year":"2011","unstructured":"Porcelli S, Fabbri C, Spina E, Serretti A, De Ronchi D (2011) Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 7(9):1101\u20131115","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"305_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/10398562.2010.498516","volume":"18","author":"G Parker","year":"2010","unstructured":"Parker G, Rowe M, Mehta F, Kumar S (2010) Will a new genotyping test help the clinician predict response to antidepressant drugs? Australas Psychiatry 18(5):413\u2013416","journal-title":"Australas Psychiatry"},{"key":"305_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0447.2001.00299.x","volume":"104","author":"J Kirchheiner","year":"2001","unstructured":"Kirchheiner J, Br\u00f8sen K, Dahl ML, Gram LF, Kasper S, Roots I et al (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173\u2013192","journal-title":"Acta Psychiatr Scand"},{"key":"305_CR23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/YIC.0b013e32832e5b0d","volume":"24","author":"A Serretti","year":"2009","unstructured":"Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecubrier Y et al (2009) Cytochrome P450, CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with the response and remission in a sample of depressive patients. Int Clin Psycopharmacol 24:250\u2013256","journal-title":"Int Clin Psycopharmacol"},{"issue":"1","key":"305_CR24","first-page":"85","volume":"22","author":"Z-H Liu","year":"2001","unstructured":"Liu Z-H, Shu Y, Huang S-L, Wang L-S, He N, Zhou H\u2013H (2001) Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin 22(1):85\u201390","journal-title":"Acta Pharmacol Sin"},{"key":"305_CR25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2125.1997.00601.x","volume":"44","author":"J Schmider","year":"1997","unstructured":"Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 44:495\u2013498","journal-title":"Br J Clin Pharmacol"},{"key":"305_CR26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00228-003-0588-0","volume":"59","author":"P Dorado","year":"2003","unstructured":"Dorado P, Berecz R, Norberto MJ, Yasar \u00dc, Dahl ML, Llerena A (2003) CYP2C9 genotypes and diclofenaco metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 59:221\u2013225","journal-title":"Eur J Clin Pharmacol"},{"key":"305_CR27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1472-8206.2004.00292.x","volume":"18","author":"JL Dorne","year":"2004","unstructured":"Dorne JL (2004) Impact of interindividual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol 18:609\u2013620","journal-title":"Fundam Clin Pharmacol"},{"key":"305_CR28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.0306-5251.2001.01402.x","volume":"52","author":"ZQ Liu","year":"2001","unstructured":"Liu ZQ, Cheng ZN, Huang SL, Chen XP, Ou-Yang DS, Jiang CH et al (2001) Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol 52:96\u201399","journal-title":"Br J Clin Pharmacol"},{"key":"305_CR29","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/ajmg.b.31081","volume":"153B","author":"SC Sim","year":"2010","unstructured":"Sim SC, Nordin L, Andersson TM-L, Virding S, Olsson M, Pedersen NL et al (2010) Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet Part B 153B:1160\u20131166","journal-title":"Am J Med Genet Part B"},{"key":"305_CR30","doi-asserted-by":"crossref","unstructured":"Yokoi T (2009) Essentials for starting a pediatric clinical study (1): pharmacokinetics in children. J Toxicol Sci 34 Suppl 2:SP307\u201312","DOI":"10.2131\/jts.34.SP307"},{"key":"305_CR31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.spen.2010.10.002","volume":"17","author":"GD Anderson","year":"2010","unstructured":"Anderson GD (2010) Developmental pharmacokinetics. Semin Pediatr Neurol 17:208\u2013213","journal-title":"Semin Pediatr Neurol"},{"key":"305_CR32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/FTD.0b013e31819f3328","volume":"31","author":"S Pichini","year":"2009","unstructured":"Pichini S, Papaseit E, Joya X, Vall O, Farr\u00e9 M, Garc\u00eda-Algar O et al (2009) Pharmacokinetics and therapeutic drugs monitoring of phychotropic drugs in pediatrics. Ther Drug Monit 31:283\u2013318","journal-title":"Ther Drug Monit"},{"key":"305_CR33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ddrr.122","volume":"16","author":"JN Anker Van den","year":"2010","unstructured":"Van den Anker JN (2010) Developmental Pharmacology. Dev Disabil Res Rev 16:233\u2013238","journal-title":"Dev Disabil Res Rev"},{"issue":"1\u20132","key":"305_CR34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/cap.2006.16.131","volume":"16","author":"RL Findling","year":"2006","unstructured":"Findling RL, McNamara NK, Stansbrey RJ, Feeny NC, Young CM, Peric FV et al (2006) The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 16(1\u20132):131\u2013145","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"305_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2350-5-27","volume":"5","author":"A Serreti","year":"2004","unstructured":"Serreti A, Smeraldi E (2004) Neural network analysis in pharmacogenetics of mood disorders. BMC Med Genet 5:27","journal-title":"BMC Med Genet"},{"key":"305_CR36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.mp.4001502","volume":"9","author":"EJ Peters","year":"2004","unstructured":"Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP (2004) Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 9:879\u2013889","journal-title":"Mol Psychiatry"},{"key":"305_CR37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0006-3223(03)00424-4","volume":"54","author":"RH Perlis","year":"2003","unstructured":"Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM et al (2003) Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 54:879\u2013883","journal-title":"Biol Psychiatry"},{"key":"305_CR38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1017\/S1461145703003663","volume":"6","author":"PR Joyce","year":"2003","unstructured":"Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR et al (2003) Age-dependent antidepressant pharmacogenomics: polymorphisms of serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortyptiline. Int J Neuropsychopharmacol 6:339\u2013346","journal-title":"Int J Neuropsychopharmacol"},{"key":"305_CR39","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/sj.mp.4001141","volume":"7","author":"YW-Y Yu","year":"2002","unstructured":"Yu YW-Y, Tsai S-J, Chen T-J, Lin C-H, Hong C-J (2002) Association study of serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7:1115\u20131119","journal-title":"Mol Psychiatry"},{"key":"305_CR40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.tpj.6500340","volume":"6","author":"C-J Hong","year":"2006","unstructured":"Hong C-J, Chen T-J, Yu YW-Y, Tsai S-J (2006) Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 6:27\u201333","journal-title":"Pharmacogenomics J"},{"key":"305_CR41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00001756-200001170-00042","volume":"11","author":"DK Kim","year":"2000","unstructured":"Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al (2000) Serotonin transporter gene polymorphism and antidepressant response. NeuroReport 11:215\u2013219","journal-title":"NeuroReport"},{"issue":"13","key":"305_CR42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/jama.296.13.1609","volume":"296","author":"H Kim","year":"2006","unstructured":"Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK (2006) Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 296(13):1609\u20131618","journal-title":"JAMA"},{"key":"305_CR43","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.1083968","volume":"301","author":"A Caspi","year":"2003","unstructured":"Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386\u2013389","journal-title":"Science"},{"key":"305_CR44","first-page":"524","volume":"39","author":"C Aslund","year":"2009","unstructured":"Aslund C, Leppert J, Comasco E, Nordquist N, Oreland L, Nilsson KW (2009) Impact of the interaction between the 5HTTLPR polymorphism and maltreatment on adolescent depression. Popul Based Study 39:524\u2013531","journal-title":"Popul Based Study"},{"issue":"9003","key":"305_CR45","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(96)90079-3","volume":"374","author":"D Ogilvie","year":"1996","unstructured":"Ogilvie D, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM et al (1996) Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 374(9003):731\u2013733","journal-title":"Lancet"},{"key":"305_CR46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.mp.4001488","volume":"9","author":"KM Smits","year":"2004","unstructured":"Smits KM, Smits LJM, Schouten JSAG, Stelma FF, Nelemans P, Prins MH (2004) Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 9:433\u2013441","journal-title":"Mol Psychiatry"},{"key":"305_CR47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/YPG.0b013e3283050aca","volume":"18","author":"KM Smits","year":"2008","unstructured":"Smits KM, Smits LJM, Peeters F, Schouten J, Janssen R, Smeets H et al (2008) The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective reuptake inhibitors in depressive patients. Psychiatr Genet 18:184\u2013190","journal-title":"Psychiatr Genet"},{"issue":"2","key":"305_CR48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1176\/appi.ajp.2009.09040576","volume":"167","author":"D Brent","year":"2010","unstructured":"Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, Ryan N et al (2010) Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) Study. Am J Psychiatry 167(2):190\u2013197","journal-title":"Am J Psychiatry"},{"key":"305_CR49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.biopsych.2005.04.048","volume":"58","author":"JB Kraft","year":"2005","unstructured":"Kraft JB, Slager SL, McGrath PJ, Hamilton SP (2005) Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58:374\u2013381","journal-title":"Biol Psychiatry"},{"key":"305_CR50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/YIC.0b013e328338bcf4","volume":"25","author":"M Noro","year":"2010","unstructured":"Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecubrier Y et al (2010) 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psycopharmacol 25:228\u2013231","journal-title":"Int Clin Psycopharmacol"},{"key":"305_CR51","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/WNR.0b013e32832eb708","volume":"20","author":"A Illi","year":"2009","unstructured":"Illi A, Set\u00e4l\u00e4-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N et al (2009) 5-HTRA1, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. NeuroReport 20:1125\u20131128","journal-title":"NeuroReport"},{"key":"305_CR52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/YPG.0b013e3282f08ab8","volume":"18","author":"SA Shaikh","year":"2008","unstructured":"Shaikh SA, Strauss J, King N, Bulgin NL, Vetr\u00f3 A, Kiss E et al (2008) Association study of serotonin system genes in childhood-onset mood disorder. Psychiatr Genet 18:47\u201352","journal-title":"Psychiatr Genet"},{"key":"305_CR53","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00213-010-2034-1","volume":"213","author":"HS Wang","year":"2011","unstructured":"Wang HS, Yeh TL, Chang HH, Gean PW, Chi MH, Yang YK et al (2011) TPH1 is associated with major depressive disorder but not with SSRI\/SNRI response in Taiwanese patients. Psycopharmacology (Berl) 213:773\u2013779","journal-title":"Psycopharmacology (Berl)"},{"key":"305_CR54","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.pnpbp.2009.02.020","volume":"33","author":"SJ Tsai","year":"2009","unstructured":"Tsai SJ, Hong CJ, Liou YJ, Yu Y-W, Chen TJ, Hou SJ et al (2009) Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 33:637\u2013641","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"305_CR55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2004.12.014","volume":"45","author":"X Zhang","year":"2005","unstructured":"Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB et al (2005) Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45:11\u201316","journal-title":"Neuron"},{"key":"305_CR56","doi-asserted-by":"crossref","unstructured":"Yu Y W-Y, Tsai S-J, Hong C-J, Chen T-JM, Chen M-C, Yang C-W (2005) Association study of monoamine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsycopharmacology 30(9):1719\u20131723","DOI":"10.1038\/sj.npp.1300785"},{"key":"305_CR57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jad.2008.04.017","volume":"113","author":"SJ Tsai","year":"2009","unstructured":"Tsai SJ, Gau Y-TA, Hong C-J, Liou Y-J, Yu YW-Y, Chen T-J (2009) Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 113:183\u2013187","journal-title":"J Affect Disord"},{"key":"305_CR58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2005.11.008","volume":"90","author":"B Arias","year":"2006","unstructured":"Arias B, Serretti A, Lorenzi C, Gast\u00f3 C, Catal\u00e1n R, Fa\u00f1an\u00e1s L (2006) Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 90:251\u2013256","journal-title":"J Affect Disord"},{"key":"305_CR59","doi-asserted-by":"crossref","unstructured":"Middeldorp CM, Slof-Op\u2019T Landt MCT, Medland SE, Van Beijsterveldt CEM, Bartels M, Willemsen G et al (2010) Anxiety and depression in children and adults: influence of serotonergic and neurotrophic genes? Genes Brain Behav 9:808\u2013816","DOI":"10.1111\/j.1601-183X.2010.00619.x"},{"key":"305_CR60","doi-asserted-by":"crossref","unstructured":"Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123B(1):19\u201322","DOI":"10.1002\/ajmg.b.20026"},{"key":"305_CR61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00213-011-2190-y","volume":"216","author":"I Allaman","year":"2011","unstructured":"Allaman I, Fiurmelli H, Magistretti PJ, Martin JL (2011) Fluoxetine regulates the expression of neurotrophic\/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 216:75\u201384","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"305_CR62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000265132","volume":"61","author":"YF Zou","year":"2010","unstructured":"Zou YF, Wang Y, Liu P, Feng XL, Wang BY, Zang TH et al (2010) Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in chinese major depressive patients. Neuropychobiology 61(2):71\u201378","journal-title":"Neuropychobiology"},{"key":"305_CR63","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.biopsych.2009.05.017","volume":"66","author":"E Real","year":"2009","unstructured":"Real E, Gratac\u00f2s M, Soria V, Escaram\u00eds G, Alonso P, Segal\u00e0s C et al (2009) A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive\u2013compulsive disorder. Biol Psychiatry 66:674\u2013680","journal-title":"Biol Psychiatry"},{"key":"305_CR64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pnpbp.2010.03.003","volume":"34","author":"GN Pandey","year":"2010","unstructured":"Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri M (2010) Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 34:645\u2013651","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"305_CR65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neulet.2006.12.013","volume":"414","author":"Z Liu","year":"2007","unstructured":"Liu Z, Zhu F, Wang G, Xio Z, Tang J, Liu W et al (2007) Association study of corticotrophin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414:155\u2013158","journal-title":"Neurosci Lett"},{"key":"305_CR66","doi-asserted-by":"crossref","unstructured":"Licino J, O\u00a1Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R et al (2004) Association of corticotrophin-releasing hormone receptor1 haplotype and antidepressant treatment response in Mexican\u2013Americans. Mol Psychiatry 9:1075\u20131082","DOI":"10.1038\/sj.mp.4001587"},{"key":"305_CR67","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/mp.2009.92","volume":"14","author":"C Dong","year":"2009","unstructured":"Dong C, Wonf M-L, Licino J (2009) Sequence variations of ABCB1, SLC6A2, SCL6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican\u2013Americans. Mol Psychiatry 14:1105\u20131118","journal-title":"Mol Psychiatry"},{"key":"305_CR68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00406-009-0091-4","volume":"260","author":"A Zobel","year":"2010","unstructured":"Zobel A, Maier W (2010) Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci 260:407\u2013417","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"12","key":"305_CR69","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/ng1479","volume":"36","author":"EB Binder","year":"2004","unstructured":"Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, P\u00fctz B et al (2004) Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36(12):1319\u20131325","journal-title":"Nat Genet"},{"issue":"3","key":"305_CR70","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/npp.2009.180","volume":"35","author":"S Horstmann","year":"2010","unstructured":"Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, M\u00fcller-Myhsok B, Holsboer F, Binder EB (2010) Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35(3):727\u2013740","journal-title":"Neuropsychopharmacology"},{"key":"305_CR71","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1749-6632.2009.05012.x","volume":"1179","author":"S Claes","year":"2009","unstructured":"Claes S (2009) Glucocorticoid receptor polymorphisms in major depression. Ann N Y Acad Sci 1179:216\u2013228","journal-title":"Ann N Y Acad Sci"},{"key":"305_CR72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/tpj.2009.12","volume":"9","author":"R Uher","year":"2009","unstructured":"Uher R, Huezo-D\u00edaz P, Perroud N, Smith R, Rietschel M, Mors O et al (2009) Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9:225\u2013233","journal-title":"Pharmacogenomics J"},{"key":"305_CR73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jad.2010.06.025","volume":"128","author":"A Serretti","year":"2011","unstructured":"Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S et al (2011) A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 128:56\u201363","journal-title":"J Affect Disord"},{"key":"305_CR74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajmg.b.30201","volume":"137B","author":"I Burcescu","year":"2005","unstructured":"Burcescu I, Wigg K, King N, Vetro A, Kiss E, Katay L et al (2005) Association study of CREB1 and childhood-onset mood disorders. Am J Med Genet B Neuropsychiatr Genet 137B:45\u201350","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"305_CR75","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coph.2006.08.014","volume":"7","author":"AL Hebb","year":"2007","unstructured":"Hebb AL, Robertson HA (2007) Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 7:86\u201392","journal-title":"Curr Opin Pharmacol"},{"issue":"41","key":"305_CR76","doi-asserted-by":"crossref","first-page":"15124","DOI":"10.1073\/pnas.0602795103","volume":"103","author":"M-L Wong","year":"2006","unstructured":"Wong M-L, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM et al (2006) Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 103(41):15124\u201315129","journal-title":"Proc Natl Acad Sci USA"},{"key":"305_CR77","first-page":"163","volume":"5","author":"H-R Luo","year":"2009","unstructured":"Luo H-R, Wu G-S, Dong C, Arcos-Burgos M, Ribeiro L, Licino J et al (2009) Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatr Dis Treat 5:163\u2013170","journal-title":"Neuropsychiatr Dis Treat"},{"key":"305_CR78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/07853890802441169","volume":"41","author":"K Esposito","year":"2009","unstructured":"Esposito K, Reierson G, Luo HR, Wu GS, Licinio J, Wong M-L (2009) Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 41:177\u2013185","journal-title":"Ann Med"},{"key":"305_CR79","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/sj.npp.1300439","volume":"29","author":"X Li","year":"2004","unstructured":"Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29:1426\u20131431","journal-title":"Neuropsychopharmacology"},{"key":"305_CR80","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.tpj.6500486","volume":"8","author":"S-J Tsai","year":"2008","unstructured":"Tsai S-J, Liou Y-J, Hong C-J, Yu YW-Y, Chen T-J (2008) Glycogen synthase kinase-3b gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 8:384\u2013390","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"305_CR81","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/FPC.0b013e328308bbc0","volume":"18","author":"SJ Tsai","year":"2008","unstructured":"Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ (2008) Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genomics 18(10):869\u2013875","journal-title":"Pharmacogenet Genomics"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-012-0305-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00787-012-0305-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-012-0305-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:27:01Z","timestamp":1743719221000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-012-0305-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,12]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1007\/s00787-012-0305-6","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,12]]}}}